| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0090-4295(98)00501-9 |
| P698 | PubMed publication ID | 9933034 |
| P2093 | author name string | N J Vogelzang | |
| W M Stadler | |||
| P2860 | cites work | A phase I clinical, plasma, and cellular pharmacology study of gemcitabine | Q28334915 |
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group | Q33488031 | ||
| Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer | Q33489195 | ||
| Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients | Q33490971 | ||
| Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study | Q33492710 | ||
| Carboplatin and urothelial tumors | Q33493074 | ||
| Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma | Q33499366 | ||
| Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma | Q33499595 | ||
| Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer | Q33500776 | ||
| Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer | Q33501053 | ||
| Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen | Q33501448 | ||
| Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial | Q33503343 | ||
| Cancer statistics, 1998. | Q34065873 | ||
| Oral piritrexim, an effective treatment for metastatic urothelial cancer | Q34360273 | ||
| Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter | Q36116031 | ||
| Advanced breast cancer: a phase II trial with gemcitabine | Q40435002 | ||
| Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial | Q40680796 | ||
| Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial | Q40704537 | ||
| A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 | ||
| Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma | Q40905847 | ||
| Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study | Q41005102 | ||
| Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine | Q41166747 | ||
| Fatal pulmonary toxicity resulting from treatment with gemcitabine | Q41525802 | ||
| Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical Phase II study | Q42548441 | ||
| Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse | Q43419722 | ||
| A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract | Q46565121 | ||
| An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. | Q54214610 | ||
| Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. | Q54418734 | ||
| Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel | Q57265736 | ||
| Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel | Q57905110 | ||
| A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors | Q68514585 | ||
| Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer | Q68891233 | ||
| Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern | Q69401186 | ||
| M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience | Q69654530 | ||
| A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer | Q71528572 | ||
| Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy | Q71667709 | ||
| Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer | Q71975358 | ||
| Oral piritrexim in advanced bladder cancer: an effective drug after progression on MVAC chemotherapy? | Q72204401 | ||
| Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group | Q72426675 | ||
| The cure of bladder cancer: the need for multidisciplinary efforts | Q72775138 | ||
| Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q73494793 | ||
| Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma | Q74545986 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 243-250 | |
| P577 | publication date | 1999-02-01 | |
| P1433 | published in | Urology | Q7900884 |
| P1476 | title | Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer | |
| P478 | volume | 53 |
| Q27026717 | Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough? |
| Q33362483 | Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group |
| Q33978830 | Paclitaxel and carboplatin in bladder cancer: recent developments |
| Q33369533 | The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group |
Search more.